We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

117 hedge funds and large institutions have $593M invested in Sutro Biopharma in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 39

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.02% less ownership

Funds ownership: 8.63% → 8.62% (-0.02%)

3% less funds holding

Funds holding: 120 → 117 (-3)

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

21% less capital invested

Capital invested by funds: $753M → $593M (-$160M)

99% less call options, than puts

Call options by funds: $24K | Put options by funds: $1.99M

Holders
117
Holders Change
-3
Holders Change %
-2.5%
% of All Funds
1.8%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
14
Increased
44
Reduced
39
Closed
17
Calls
$24K
Puts
$1.99M
Net Calls
-$1.96M
Net Calls Change
-$1.97M

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$6.06M
2
Franklin Resources
Franklin Resources
California
+$5.65M
3
FM
Frazier Management
Washington
+$5.51M
4
SCM
Suvretta Capital Management
New York
+$3.66M
5
OM
Opaleye Management
Massachusetts
+$2.55M

Top Sellers

Rank Fund Capital Flow
1
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$8.13M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.08M
3
WP
Woodline Partners
California
-$4.15M
4
Invesco
Invesco
Georgia
-$3.21M
5
N
Nuveen
North Carolina
-$3.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
51
Walleye Capital
New York
$1.12M +$1.35M +7,541 New
Citigroup
52
Citigroup
New York
$1.08M +$545K +3,043 +72%
GCP
53
GSA Capital Partners
United Kingdom
$1.06M +$1.28M +7,141 New
Swiss National Bank
54
Swiss National Bank
Switzerland
$1.05M – – –
Morgan Stanley
55
Morgan Stanley
New York
$946K +$669K +3,736 +143%
Deutsche Bank
56
Deutsche Bank
Germany
$850K +$25.1K +140 +3%
JP Morgan Chase
57
JP Morgan Chase
New York
$836K -$10K -56 -1%
State of Wisconsin Investment Board
58
State of Wisconsin Investment Board
Wisconsin
$835K – – –
RhumbLine Advisers
59
RhumbLine Advisers
Massachusetts
$833K +$13.1K +73 +1%
Wells Fargo
60
Wells Fargo
California
$777K -$1.09M -6,060 -54%
Allianz Asset Management
61
Allianz Asset Management
Germany
$768K -$483K -2,696 -34%
California State Teachers Retirement System (CalSTRS)
62
California State Teachers Retirement System (CalSTRS)
California
$757K +$19.3K +108 +2%
Renaissance Technologies
63
Renaissance Technologies
New York
$725K +$872K +4,870 New
ECM
64
ExodusPoint Capital Management
New York
$714K +$408K +2,275 +90%
DCM
65
DAFNA Capital Management
California
$670K -$717K -4,000 -47%
Los Angeles Capital Management
66
Los Angeles Capital Management
California
$610K – – –
HF
67
HRT Financial
New York
$585K +$705K +3,938 New
Principal Financial Group
68
Principal Financial Group
Iowa
$562K -$505K -2,817 -43%
Susquehanna International Group
69
Susquehanna International Group
Pennsylvania
$562K +$150K +838 +29%
Squarepoint
70
Squarepoint
New York
$562K +$476K +2,657 +237%
CPM
71
Connective Portfolio Management
New York
$527K +$627K +3,500 New
Allspring Global Investments
72
Allspring Global Investments
North Carolina
$519K +$625K +3,490 New
New York State Common Retirement Fund
73
New York State Common Retirement Fund
New York
$465K -$1.25K -7 -0.2%
MAM
74
Martingale Asset Management
Massachusetts
$457K +$549K +3,062 New
D.E. Shaw & Co
75
D.E. Shaw & Co
New York
$456K -$121K -673 -18%
1 2
3
4 5

STRO Hedge Fund Activity: Q4 2021 in Review

117 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2021, worth a combined $593M — down 21% from $753M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of STRO and 14 opened new positions — a net loss of 3 holders — while 39 trimmed existing stakes and 44 added.

The largest buyer was Eventide Asset Management, adding an estimated $6.06M. The largest seller was Loomis, Sayles & Company, cutting an estimated $8.13M.

  • 117 institutional investors held Sutro Biopharma (STRO) as of Q4 2021, down from 120 in Q3 2021.
  • Funds reported $593M of Sutro Biopharma stock for Q4 2021, down 21% quarter-over-quarter.
  • 14 funds opened new Sutro Biopharma positions in Q4 2021 and 17 closed out, a net change of -3 holders.
  • The largest Sutro Biopharma buyer in Q4 2021 was Eventide Asset Management, an estimated $6.06M added.
  • The largest Sutro Biopharma seller in Q4 2021 was Loomis, Sayles & Company, an estimated $8.13M sold.

Based on aggregated 13F filings for Q4 2021.